+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Anticonvulsants Market - Global Forecast 2026-2032- Product Image
Anticonvulsants Market - Global Forecast 2026-2032- Product Image
Sale

Anticonvulsants Market - Global Forecast 2026-2032

  • Report

  • 186 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 5305569
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Anticonvulsants Market is projected to reach USD 15.50 Billion in 2026. It is expected to continue growing at a CAGR of 8.97%, reaching USD 25.98 Billion by 2032.

The anticonvulsants market is anchored by the sustained clinical burden of epilepsy, neuropathic pain, bipolar disorder, migraine prevention, and other neurologic conditions where seizure control and neuronal excitability management are central treatment goals. The World Health Organization identifies epilepsy as one of the most common neurological diseases globally, affecting about 50 million people, with nearly 80% living in low- and middle-income countries. This creates durable demand for both established antiseizure medicines and newer therapies designed to improve tolerability, adherence, and refractory seizure outcomes.

Market momentum is shaped by expanding diagnosis, broader use of generics, specialist-led adoption of novel mechanisms, and payer scrutiny around branded therapies. Widely used active ingredients such as levetiracetam, lamotrigine, valproate, carbamazepine, topiramate, lacosamide, and brivaracetam continue to define prescribing patterns, while rare epilepsy syndromes and precision neurology are encouraging investment in differentiated anticonvulsant pipelines.

Transformative Shifts in the Anticonvulsants Landscape

The anticonvulsants landscape is shifting from broad symptom suppression toward precision seizure management, where therapy selection increasingly considers seizure type, comorbidities, pregnancy risk, drug-drug interactions, pharmacogenomics, and long-term cognitive or behavioral effects. Clinicians are also prioritizing simplified dosing and improved tolerability because adherence remains a key determinant of seizure control.

Another major transformation is the growing role of specialty therapies for treatment-resistant epilepsy and rare syndromes, including Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex. At the same time, generic penetration is intensifying price competition in mature markets, pushing manufacturers to differentiate through formulation innovation, pediatric indications, real-world evidence, and lifecycle management.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a cumulative enabler across the anticonvulsants value chain, from target discovery and molecular screening to trial design, patient stratification, and safety monitoring. AI-supported analysis of electroencephalogram data, electronic health records, imaging, and genomics can help identify seizure patterns, predict treatment response, and support earlier intervention in patients at risk of uncontrolled epilepsy.

For manufacturers and healthcare systems, AI has practical impact in pharmacovigilance, medication adherence analytics, supply planning, and evidence generation. The strongest near-term opportunities are expected where AI complements clinician decision-making, improves trial recruitment for rare epilepsy populations, and detects adverse event signals earlier without replacing validated clinical judgment or regulatory-grade evidence.

Key Regional Insights Across Anticonvulsants

Asia-Pacific is a high-volume region for anticonvulsants due to large patient pools, improving neurology access, rising diagnosis, and strong generic manufacturing capacity, with China, India, Japan, South Korea, and Australia shaping different parts of the value chain. North America remains innovation-led, supported by specialist epilepsy centers, advanced reimbursement pathways, regulated therapy adoption, and strong uptake of newer branded antiseizure medicines where clinical value is demonstrated.

Europe is characterized by evidence-based prescribing, health technology assessment, generic uptake, and cross-country variation in reimbursement, while Latin America shows expanding demand through public-sector access programs and private neurology care in urban markets. The Middle East is benefiting from hospital investment and specialist care expansion, particularly in Gulf countries, whereas Africa has a substantial unmet treatment gap due to limited neurologist availability, medicine affordability challenges, and uneven access to diagnostic tools such as electroencephalography.

Key Group Insights for Strategic Market Planning

ASEAN markets are expanding through improved public healthcare coverage, rising epilepsy awareness, and broader access to cost-effective generics, although diagnostic infrastructure varies significantly between urban and rural settings. The GCC is differentiated by hospital-led specialty care, government healthcare funding, and increasing adoption of advanced neurology services, supporting demand for both established and innovative anticonvulsants.

The European Union remains a benchmark for regulatory rigor, pharmacovigilance, and payer-led value assessment, while BRICS countries combine large treatment populations with strong domestic manufacturing and pricing pressure. G7 markets are central to clinical research, premium product launches, and real-world evidence generation. NATO-aligned countries, many of which overlap with advanced Western healthcare systems, emphasize supply security, regulatory harmonization, and resilient access to essential neurological medicines.

Key Country Insights in Major Anticonvulsants Markets

The United States leads in branded anticonvulsant innovation, rare epilepsy treatment adoption, and specialty neurology services, while Canada emphasizes publicly managed access, guideline-based use, and cost-effectiveness. Mexico and Brazil provide growth through expanding healthcare coverage and generic utilization, although access varies by payer and region. The United Kingdom, Germany, France, Italy, and Spain show mature demand shaped by reimbursement evaluation, generic substitution, and specialist prescribing, while Russia remains influenced by local procurement dynamics and availability of essential medicines.

China and India are major demand and supply markets, combining large epilepsy populations with strong domestic production and increasing clinical research capacity. Japan prioritizes quality, safety, and aging-population needs, while South Korea supports advanced hospital care and digital health integration. Australia demonstrates high guideline adherence and specialist access, reinforcing steady demand for both established and newer antiseizure therapies.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated clinical value, not only molecule novelty. Winning strategies include investing in therapies for refractory epilepsy, pediatric seizure disorders, improved formulations, pregnancy-safe evidence packages, and adherence-supporting delivery profiles. Manufacturers should also strengthen post-marketing evidence because real-world tolerability, seizure freedom, persistence, and quality-of-life outcomes increasingly influence payer and prescriber decisions.

Commercial teams should localize access models by region, pairing premium innovation with affordable generics and patient-assistance pathways where needed. Supply chain resilience, active pharmaceutical ingredient diversification, physician education, and AI-enabled pharmacovigilance should be treated as strategic priorities rather than operational add-ons.

Research Methodology

This executive summary is based on triangulation of publicly available clinical, regulatory, epidemiological, and market-structure evidence from authoritative sources, including global health agencies, medicine regulators, peer-reviewed neurology literature, and treatment guidelines. Emphasis is placed on verified disease burden, therapeutic use patterns, regional access conditions, and observable shifts in innovation and commercialization.

The methodology combines secondary research, qualitative market interpretation, therapy-area mapping, and regional segmentation. Insights are validated for consistency across epidemiology, prescribing behavior, reimbursement trends, generic competition, and emerging technology adoption, while avoiding unsupported market sizing or unverifiable forecasts.

Conclusion

The anticonvulsants market is evolving from a mature drug class into a more specialized, evidence-driven segment of neurology care. Established generics will continue to provide the backbone of seizure management, while innovation will concentrate on refractory epilepsy, rare syndromes, better safety profiles, and patient-centered outcomes.

Long-term leadership will depend on balancing affordability, clinical differentiation, regulatory credibility, and reliable access. Organizations that combine scientific rigor with regional execution, AI-enabled evidence generation, and resilient supply strategies will be best positioned to support sustainable growth in anticonvulsants.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Anticonvulsants Market, by Drug Class
7.1. Introduction
7.2. Benzodiazepines
7.2.1. Clobazam
7.2.2. Clonazepam
7.2.3. Diazepam
7.3. Carbonic Anhydrase Inhibitors
7.3.1. Acetazolamide
7.3.2. Methazolamide
7.4. Gaba Analogues
7.4.1. Gabapentin
7.4.2. Pregabalin
7.4.3. Vigabatrin
7.5. Sodium Channel Blockers
7.5.1. Carbamazepine
7.5.2. Lamotrigine
7.5.3. Phenytoin
7.6. Sv2A Modulators
7.6.1. Brivaracetam
7.6.2. Levetiracetam
8. Anticonvulsants Market, by Indication
8.1. Introduction
8.2. Bipolar Disorder
8.2.1. Type I
8.2.2. Type II
8.3. Epilepsy
8.3.1. Absence Seizures
8.3.2. Focal Seizures
8.3.3. Generalized Seizures
8.3.4. Myoclonic Seizures
8.3.5. Status Epilepticus
8.4. Migraine Prophylaxis
8.5. Neuropathic Pain
8.5.1. Diabetic Neuropathy
8.5.2. Postherpetic Neuralgia
9. Anticonvulsants Market, by Route Of Administration
9.1. Introduction
9.2. Injectable
9.3. Oral
9.4. Rectal
9.5. Transdermal
10. Anticonvulsants Market, by Age Group
10.1. Introduction
10.2. Pediatric
10.3. Adult
10.4. Geriatric
11. Anticonvulsants Market, by Distribution Channel
11.1. Introduction
11.2. Online
11.3. Offline
12. Anticonvulsants Market, by End User
12.1. Introduction
12.2. Hospitals
12.3. Clinics
12.4. Homecare
12.5. Research Institutes
13. Anticonvulsants Market, by Region
13.1. Asia-Pacific
13.2. North America
13.3. Latin America
13.4. Europe
13.5. Middle East
13.6. Africa
14. Anticonvulsants Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Anticonvulsants Market, by Country
15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. FPNV Positioning Matrix, 2025
16.3. Market Concentration Analysis, 2025
16.3.1. Concentration Ratio (CR)
16.3.2. Herfindahl Hirschman Index (HHI)
16.4. Recent Developments & Impact Analysis, 2025
16.5. Product Portfolio Analysis, 2025
16.6. Benchmarking Analysis, 2025
17. Company Profiles
17.1. Abbott Laboratories
17.2. Bausch Health Companies Inc.
17.3. Biocon Limited
17.4. Cadila Pharmaceuticals Limited
17.5. Cipla, Inc.
17.6. Dr. Reddy's Laboratories Limited
17.7. Eisai Co., Ltd.
17.8. GlaxoSmithKline PLC
17.9. Glenmark Pharmaceuticals Ltd.
17.10. Jazz Pharmaceuticals, Inc.
17.11. Johnson & Johnson Services, Inc.
17.12. Lifecare Neuro Products Limited
17.13. Lundbeck A/S
17.14. Mankind Pharma Ltd.
17.15. Merck KGaA
17.16. Novartis AG
17.17. Novo Nordisk A/S
17.18. Otsuka Pharmaceutical Co., Ltd.
17.19. Pfizer Inc.
17.20. Sanofi S.A.
17.21. Sunovion Pharmaceuticals Inc.
17.22. Takeda Pharmaceutical Company Limited
17.23. Teva Pharmaceutical Industries Ltd.
17.24. Wockhardt Limited
List of Figures
FIGURE 1. GLOBAL ANTICONVULSANTS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL ANTICONVULSANTS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL ANTICONVULSANTS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL ANTICONVULSANTS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL ANTICONVULSANTS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
FIGURE 7. GLOBAL ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
FIGURE 9. GLOBAL ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 11. GLOBAL ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL ANTICONVULSANTS MARKET SIZE, BY AGE GROUP, 2025 VS 2032 (%)
FIGURE 13. GLOBAL ANTICONVULSANTS MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 15. GLOBAL ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL ANTICONVULSANTS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 17. GLOBAL ANTICONVULSANTS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL ANTICONVULSANTS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL ANTICONVULSANTS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL ANTICONVULSANTS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 21. GLOBAL ANTICONVULSANTS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 23. GLOBAL ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL ANTICONVULSANTS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 25. GLOBAL ANTICONVULSANTS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL ANTICONVULSANTS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL ANTICONVULSANTS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL BENZODIAZEPINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL BENZODIAZEPINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL BENZODIAZEPINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL CLOBAZAM MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL CLOBAZAM MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL CLOBAZAM MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL CLONAZEPAM MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL CLONAZEPAM MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL CLONAZEPAM MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL DIAZEPAM MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL DIAZEPAM MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL DIAZEPAM MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL CARBONIC ANHYDRASE INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL CARBONIC ANHYDRASE INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL CARBONIC ANHYDRASE INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL ACETAZOLAMIDE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL ACETAZOLAMIDE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL ACETAZOLAMIDE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL METHAZOLAMIDE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL METHAZOLAMIDE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL METHAZOLAMIDE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL GABA ANALOGUES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL GABA ANALOGUES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL GABA ANALOGUES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL GABAPENTIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL GABAPENTIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL GABAPENTIN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL PREGABALIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL PREGABALIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL PREGABALIN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL VIGABATRIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL VIGABATRIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL VIGABATRIN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL SODIUM CHANNEL BLOCKERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL SODIUM CHANNEL BLOCKERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL SODIUM CHANNEL BLOCKERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL CARBAMAZEPINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL CARBAMAZEPINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL CARBAMAZEPINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL LAMOTRIGINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL LAMOTRIGINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL LAMOTRIGINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL PHENYTOIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL PHENYTOIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL PHENYTOIN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL SV2A MODULATORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL SV2A MODULATORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL SV2A MODULATORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL BRIVARACETAM MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL BRIVARACETAM MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL BRIVARACETAM MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL LEVETIRACETAM MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL LEVETIRACETAM MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL LEVETIRACETAM MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL BIPOLAR DISORDER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL BIPOLAR DISORDER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL BIPOLAR DISORDER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL TYPE I MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL TYPE I MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL TYPE I MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL TYPE II MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL TYPE II MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL TYPE II MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL EPILEPSY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL EPILEPSY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL EPILEPSY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL ABSENCE SEIZURES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL ABSENCE SEIZURES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL ABSENCE SEIZURES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL FOCAL SEIZURES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL FOCAL SEIZURES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL FOCAL SEIZURES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL GENERALIZED SEIZURES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL GENERALIZED SEIZURES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL GENERALIZED SEIZURES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL MYOCLONIC SEIZURES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL MYOCLONIC SEIZURES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL MYOCLONIC SEIZURES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL STATUS EPILEPTICUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL STATUS EPILEPTICUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL STATUS EPILEPTICUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL MIGRAINE PROPHYLAXIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL MIGRAINE PROPHYLAXIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL MIGRAINE PROPHYLAXIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL NEUROPATHIC PAIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL NEUROPATHIC PAIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL NEUROPATHIC PAIN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL POSTHERPETIC NEURALGIA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL POSTHERPETIC NEURALGIA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL POSTHERPETIC NEURALGIA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL RECTAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL RECTAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL RECTAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL TRANSDERMAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL TRANSDERMAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL TRANSDERMAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL ANTICONVULSANTS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL ADULT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL ADULT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 117. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 118. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 119. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 120. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 121. GLOBAL ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 122. GLOBAL ONLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 123. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 124. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 125. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 126. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 127. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 128. GLOBAL ANTICONVULSANTS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 129. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 130. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 131. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 132. GLOBAL CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 133. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 134. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 135. GLOBAL HOMECARE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 136. GLOBAL HOMECARE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 137. GLOBAL HOMECARE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 138. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 139. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 140. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 141. GLOBAL ANTICONVULSANTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 142. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 143. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 144. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2017-2032 (USD MILLION)
TABLE 145. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 146. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2017-2032 (USD MILLION)
TABLE 147. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2017-2032 (USD MILLION)
TABLE 148. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2017-2032 (USD MILLION)
TABLE 149. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 150. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2017-2032 (USD MILLION)
TABLE 151. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2017-2032 (USD MILLION)
TABLE 152. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2017-2032 (USD MILLION)
TABLE 153. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 154. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 155. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 156. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 157. NORTH AMERICA ANTICONVULSANTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 158. NORTH AMERICA ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 159. NORTH AMERICA ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2017-2032 (USD MILLION)
TABLE 160. NORTH AMERICA ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 161. NORTH AMERICA ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2017-2032 (USD MILLION)
TABLE 162. NORTH AMERICA ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2017-2032 (USD MILLION)
TABLE 163. NORTH AMERICA ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2017-2032 (USD MILLION)
TABLE 164. NORTH AMERICA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 165. NORTH AMERICA ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2017-2032 (USD MILLION)
TABLE 166. NORTH AMERICA ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2017-2032 (USD MILLION)
TABLE 167. NORTH AMERICA ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2017-2032 (USD MILLION)
TABLE 168. NORTH AMERICA ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 169. NORTH AMERICA ANTICONVULSANTS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 170. NORTH AMERICA ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 171. NORTH AMERICA ANTICONVULSANTS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 172. LATIN AMERICA ANTICONVULSANTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 173. LATIN AMERICA ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 174. LATIN AMERICA ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2017-2032 (USD MILLION)
TABLE 175. LATIN AMERICA ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 176. LATIN AMERICA ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2017-2032 (USD MILLION)
TABLE 177. LATIN AMERICA ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2017-2032 (USD MILLION)
TABLE 178. LATIN AMERICA ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2017-2032 (USD MILLION)
TABLE 179. LATIN AMERICA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 180. LATIN AMERICA ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2017-2032 (USD MILLION)
TABLE 181. LATIN AMERICA ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2017-2032 (USD MILLION)
TABLE 182. LATIN AMERICA ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2017-2032 (USD MILLION)
TABLE 183. LATIN AMERICA ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 184. LATIN AMERICA ANTICONVULSANTS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 185. LATIN AMERICA ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 186. LATIN AMERICA ANTICONVULSANTS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 187. EUROPE ANTICONVULSANTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 188. EUROPE ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 189. EUROPE ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2017-2032 (USD MILLION)
TABLE 190. EUROPE ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 191. EUROPE ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2017-2032 (USD MILLION)
TABLE 192. EUROPE ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2017-2032 (USD MILLION)
TABLE 193. EUROPE ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2017-2032 (USD MILLION)
TABLE 194. EUROPE ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 195. EUROPE ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2017-2032 (USD MILLION)
TABLE 196. EUROPE ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2017-2032 (USD MILLION)
TABLE 197. EUROPE ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2017-2032 (USD MILLION)
TABLE 198. EUROPE ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 199. EUROPE ANTICONVULSANTS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 200. EUROPE ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 201. EUROPE ANTICONVULSANTS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 202. MIDDLE EAST ANTICONVULSANTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 203. MIDDLE EAST ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 204. MIDDLE EAST ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2017-2032 (USD MILLION)
TABLE 205. MIDDLE EAST ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 206. MIDDLE EAST ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2017-2032 (USD MILLION)
TABLE 207. MIDDLE EAST ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2017-2032 (USD MILLION)
TABLE 208. MIDDLE EAST ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2017-2032 (USD MILLION)
TABLE 209. MIDDLE EAST ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 210. MIDDLE EAST ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2017-2032 (USD MILLION)
TABLE 211. MIDDLE EAST ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2017-2032 (USD MILLION)
TABLE 212. MIDDLE EAST ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2017-2032 (USD MILLION)
TABLE 213. MIDDLE EAST ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 214. MIDDLE EAST ANTICONVULSANTS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 215. MIDDLE EAST ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 216. MIDDLE EAST ANTICONVULSANTS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 217. AFRICA ANTICONVULSANTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 218. AFRICA ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 219. AFRICA ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2017-2032 (USD MILLION)
TABLE 220. AFRICA ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 221. AFRICA ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2017-2032 (USD MILLION)
TABLE 222. AFRICA ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2017-2032 (USD MILLION)
TABLE 223. AFRICA ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2017-2032 (USD MILLION)
TABLE 224. AFRICA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 225. AFRICA ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2017-2032 (USD MILLION)
TABLE 226. AFRICA ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2017-2032 (USD MILLION)
TABLE 227. AFRICA ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2017-2032 (USD MILLION)
TABLE 228. AFRICA ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 229. AFRICA ANTICONVULSANTS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 230. AFRICA ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 231. AFRICA ANTICONVULSANTS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 232. GLOBAL ANTICONVULSANTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 233. ASEAN ANTICONVULSANTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 234. ASEAN ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 235. ASEAN ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2017-2032 (USD MILLION)
TABLE 236. ASEAN ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 237. ASEAN ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2017-2032 (USD MILLION)
TABLE 238. ASEAN ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2017-2032 (USD MILLION)
TABLE 239. ASEAN ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2017-2032 (USD MILLION)
TABLE 240. ASEAN ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 241. ASEAN ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2017-2032 (USD MILLION)
TABLE 242. ASEAN ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2017-2032 (USD MILLION)
TABLE 243. ASEAN ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2017-2032 (USD MILLION)
TABLE 244. ASEAN ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 245. ASEAN ANTICONVULSANTS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 246. ASEAN ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 247. ASEAN ANTICONVULSANTS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 248. GCC ANTICONVULSANTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 249. GCC ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 250. GCC ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2017-2032 (USD MILLION)
TABLE 251. GCC ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 252. GCC ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2017-2032 (USD MILLION)
TABLE 253. GCC ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2017-2032 (USD MILLION)
TABLE 254. GCC ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2017-2032 (USD MILLION)
TABLE 255. GCC ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 256. GCC ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2017-2032 (USD MILLION)
TABLE 257. GCC ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2017-2032 (USD MILLION)
TABLE 258. GCC ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2017-2032 (USD MILLION)
TABLE 259. GCC ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 260. GCC ANTICONVULSANTS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 261. GCC ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 262. GCC ANTICONVULSANTS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 263. EUROPEAN UNION ANTICONVULSANTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 264. EUROPEAN UNION ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 265. EUROPEAN UNION ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2017-2032 (USD MILLION)
TABLE 266. EUROPEAN UNION ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 267. EUROPEAN UNION ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2017-2032 (USD MILLION)
TABLE 268. EUROPEAN UNION ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2017-2032 (USD MILLION)
TABLE 269. EUROPEAN UNION ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2017-2032 (USD MILLION)
TABLE 270. EUROPEAN UNION ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 271. EUROPEAN UNION ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2017-2032 (USD MILLION)
TABLE 272. EUROPEAN UNION ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2017-2032 (USD MILLION)
TABLE 273. EUROPEAN UNION ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2017-2032 (USD MILLION)
TABLE 274. EUROPEAN UNION ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 275. EUROPEAN UNION ANTICONVULSANTS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 276. EUROPEAN UNION ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 277. EUROPEAN UNION ANTICONVULSANTS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 278. BRICS ANTICONVULSANTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 279. BRICS ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 280. BRICS ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2017-2032 (USD MILLION)
TABLE 281. BRICS ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 282. BRICS ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2017-2032 (USD MILLION)
TABLE 283. BRICS ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2017-2032 (USD MILLION)
TABLE 284. BRICS ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2017-2032 (USD MILLION)
TABLE 285. BRICS ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 286. BRICS ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2017-2032 (USD MILLION)
TABLE 287. BRICS ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2017-2032 (USD MILLION)
TABLE 288. BRICS ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2017-2032 (USD MILLION)
TABLE 289. BRICS ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 290. BRICS ANTICONVULSANTS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 291. BRICS ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 292. BRICS ANTICONVULSANTS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 293. G7 ANTICONVULSANTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 294. G7 ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 295. G7 ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2017-2032 (USD MILLION)
TABLE 296. G7 ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 297. G7 ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2017-2032 (USD MILLION)
TABLE 298. G7 ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2017-2032 (USD MILLION)
TABLE 299. G7 ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2017-2032 (USD MILLION)
TABLE 300. G7 ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 301. G7 ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2017-2032 (USD MILLION)
TABLE 302. G7 ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2017-2032 (USD MILLION)
TABLE 303. G7 ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2017-2032 (USD MILLION)
TABLE 304. G7 ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 305. G7 ANTICONVULSANTS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 306. G7 ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 307. G7 ANTICONVULSANTS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 308. NATO ANTICONVULSANTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 309. NATO ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 310. NATO ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2017-2032 (USD MILLION)
TABLE 311. NATO ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 312. NATO ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2017-2032 (USD MILLION)
TABLE 313. NATO ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2017-2032 (USD MILLION)
TABLE 314. NATO ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2017-2032 (USD MILLION)
TABLE 315. NATO ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 316. NATO ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2017-2032 (USD MILLION)
TABLE 317. NATO ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2017-2032 (USD MILLION)
TABLE 318. NATO ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2017-2032 (USD MILLION)
TABLE 319. NATO ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 320. NATO ANTICONVULSANTS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 321. NATO ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 322. NATO ANTICONVULSANTS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 323. GLOBAL ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 324. UNITED STATES ANTICONVULSANTS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 325. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 326. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2017-2032 (USD MILLION)
TABLE 327. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 328. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2017-2032 (USD MILLION)
TABLE 329. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2017-2032 (USD MILLION)
TABLE 330. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2017-2032 (USD MILLION)
TABLE 331. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 332. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2017-2032 (USD MILLION)
TABLE 333. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2017-2032 (USD MILLION)
TABLE 334. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2017-2032 (USD MILLION)
TABLE 335. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 336. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 337. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 338. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 339. CANADA ANTICONVULSANTS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 340. CANADA ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 341. CANADA ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2017-2032 (USD MILLION)
TABLE 342. CANADA ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 343. CANADA ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2017-2032 (USD MILLION)
TABLE 344. CANADA ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2017-2032 (USD MILLION)
TABLE 345. CANADA ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2017-2032 (USD MILLION)
TABLE 346. CANADA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 347. CANADA ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2017-2032 (USD MILLION)
TABLE 348. CANADA ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2017-2032 (USD MILLION)
TABLE 349. CANADA ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2017-2032 (USD MILLION)
TABLE 350. CANADA ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 351. CANADA ANTICONVULSANTS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 352. CANADA ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 353. CANADA ANTICONVULSANTS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 354. MEXICO ANTICONVULSANTS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 355. MEXICO ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 356. MEXICO ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2017-2032 (USD MILLION)
TABLE 357. MEXICO ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 358. MEXICO ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2017-2032 (USD MILLION)
TABLE 359. MEXICO ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2017-2032 (USD MILLION)
TABLE 360. MEXICO ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2017-2032 (USD MILLION)
TABLE 361. MEXICO ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 362. MEXICO ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2017-2032 (USD MILLION)
TABLE 363. MEXICO ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2017-2032 (USD MILLION)
TABLE 364. MEXICO ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2017-2032 (USD MILLION)
TABLE 365. MEXICO ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 366. MEXICO ANTICONVULSANTS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 367. MEXICO ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 368. MEXICO ANTICONVULSANTS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 369. BRAZIL ANTICONVULSANTS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 370. BRAZIL ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 371. BRAZIL ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2017-2032 (USD MILLION)
TABLE 372. BRAZIL ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 373. BRAZIL ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2017-2032 (USD MILLION)
TABLE 374. BRAZIL ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2017-2032 (USD MILLION)
TABLE 375. BRAZIL ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2017-2032 (USD MILLION)
TABLE 376. BRA

Companies Mentioned

  • Abbott Laboratories
  • Bausch Health Companies Inc.
  • Biocon Limited
  • Cadila Pharmaceuticals Limited
  • Cipla, Inc.
  • Dr. Reddy's Laboratories Limited
  • Eisai Co., Ltd.
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Ltd.
  • Jazz Pharmaceuticals, Inc.
  • Johnson & Johnson Services, Inc.
  • Lifecare Neuro Products Limited
  • Lundbeck A/S
  • Mankind Pharma Ltd.
  • Merck KGaA
  • Novartis AG
  • Novo Nordisk A/S
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Sanofi S.A.
  • Sunovion Pharmaceuticals Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Wockhardt Limited

Table Information

Report AttributeDetails
No. of Pages186
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 15.5 Billion
Forecasted Market Value ( USD ) by 2032 $ 25.98 Billion
Compound Annual Growth Rate8.9%
Regions CoveredGlobal
No. of Companies Mentioned24

Related Topics

Related Reports

Anticonvulsants Market Report 2026 - Product Image

Anticonvulsants Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Anticonvulsant Drugs Market Outlook 2026-2034: Market Share and Growth Analysis - Product Image

Anticonvulsant Drugs Market Outlook 2026-2034: Market Share and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Acute Repetitive Seizures Market Outlook 2026-2034: Market Share and Growth Analysis by Drug Type (Benzodiazepines, non-Benzodiazepines, Barbiturates, Other Drug Types (anticonvulsants, anaesthetic drugs)), Route of Administration, Distribution Channel - Product Image

Acute Repetitive Seizures Market Outlook 2026-2034: Market Share and Growth Analysis by Drug Type (Benzodiazepines, non-Benzodiazepines, Barbiturates, Other Drug Types (anticonvulsants, anaesthetic drugs)), Route of Administration, Distribution Channel

  • Report
  • 160 Pages
  • Global
From
Trigeminal Neuralgia Therapeutics Market - Global Forecast 2026-2032 - Product Image

Trigeminal Neuralgia Therapeutics Market - Global Forecast 2026-2032

  • Report
  • 183 Pages
  • Global
From
Infantile Spasms Therapeutics Market - Global Forecast 2026-2032 - Product Image

Infantile Spasms Therapeutics Market - Global Forecast 2026-2032

  • Report
  • 186 Pages
  • Global
From

About the Anticonvulsants Market

Anticonvulsants are a class of drugs used to treat seizures and other neurological disorders. They work by reducing the abnormal electrical activity in the brain that causes seizures. Anticonvulsants are used to treat a variety of conditions, including epilepsy, bipolar disorder, and neuropathic pain. They are also used to prevent seizures in people with certain types of brain injuries. Anticonvulsants are part of the larger class of Central Nervous System (CNS) drugs, which also includes antidepressants, antipsychotics, and anxiolytics. The anticonvulsant market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include Pfizer, GlaxoSmithKline, Novartis, Sanofi, and Johnson & Johnson. Other companies include Mylan, Teva Pharmaceuticals, and Sun Pharmaceuticals. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.